Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly and Co. (NYSE: LLY ) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments. The company’s obesity and diabetes franchise remained its bi